CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Fludarabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01991457
NCT01991457Phase 2Completed

Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen

University of Alabama at Birmingham·interventional·Posted Nov 25, 2013·Updated Jan 12, 2024

In Brief

A Phase 2 clinical trial evaluating Fludarabine and Total Body Irradiation for Adult Lymphoblastic Lymphoma. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical conditions. The primary objective is to establish the efficacy of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen. The investigators are also assessing the safety and toxicity of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartAug 27, 2013
Primary CompletionJan 30, 2020
Study CompletionAug 23, 2022
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 12.6 years ago

Interventions

Fludarabinedrug

Total Body Irradiationprocedure